Citations Appearing in 2019

  1. Abebe, B.T., Weiss, M., Modess, C., Roustom, T., Tadken, T., Wegner, D., Schwantes, U., Neumeister, C., Schulz, H.U., Scheuch, E. and Siegmund, W., 2019. Effects of the P‐Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4‐Way Crossover Drug‐Drug Interaction Study in Healthy Subjects. The Journal of Clinical Pharmacology, 59(10), pp.1319-1330.
  2. Abodakpi, H., Chang, K.T., Zhou, J., Byerly, C. and Tam, V.H., 2019. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae. Clinical Microbiology and Infection, 25(9), pp.1154-e9.
  3. Abodakpi, H., Chang, K.T., Gao, S., Sánchez-Díaz, A.M., Cantón, R. and Tam, V.H., 2019. Optimal piperacillin-tazobactam dosing strategies against extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrobial agents and chemotherapy, 63(2).
  4. Ahmed, B., Munir, B., Ghaffar, A., Yameen, M., Jalal, F., Farooq, M.U., Shehzadi, S., Ashraf, S. and Liaqat, A., 2019. Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. Pakistan journal of pharmaceutical sciences, 32.
  5. Akhter, T. and Sivaloganathan, S., 2019. The Incorporation of Fractal Kinetics in the PK Modeling of Chemotherapeutic Drugs with Nonlinear Concentration-Time Profiles. In Trends in Biomathematics: Mathematical Modeling for Health, Harvesting, and Population Dynamics(pp. 231-254). Springer, Cham.
  6. Allen, R. and Moore, H., 2019. Perspectives on the role of mathematics in drug discovery and development. Bulletin of mathematical biology, 81(9), pp.3425-3435.
  7. Ayyar, V.S., DuBois, D.C., Nakamura, T., Almon, R.R. and Jusko, W.J., 2019. Modeling corticosteroid pharmacokinetics and pharmacodynamics, part II: sex differences in methylprednisolone pharmacokinetics and corticosterone suppression. Journal of Pharmacology and Experimental Therapeutics, 370(2), pp.327-336.
  8. Ayyar, V.S., DuBois, D.C., Almon, R.R. and Jusko, W.J., 2019. Modeling corticosteroid pharmacokinetics and pharmacodynamics, part III: estrous cycle and estrogen receptor–dependent antagonism of glucocorticoid-induced leucine zipper (GILZ) enhancement by corticosteroids. Journal of Pharmacology and Experimental Therapeutics, 370(2), pp.337-349.
  9. Ayyar, V.S., DuBois, D.C., Almon, R.R. and Jusko, W.J., 2019. Mechanistic multi-tissue modeling of GILZ regulation: integrating circadian gene expression with receptor-mediated corticosteroid pharmacodynamics. PHARMACOKINETICS AND RECEPTOR-MEDIATED PHARMACODYNAMICS OF METHYLPREDNISOLONE, p.67.
  10. Ayyar, V.S., Krzyzanski, W. and Jusko, W.J., 2019. Indirect pharmacodynamic models for responses with circadian removal. Journal of pharmacokinetics and pharmacodynamics, 46(1), pp.89-101.
  11. Ayyar, V.S., DuBois, D.C., Nakamura, T., Almon, R.R. and Jusko, W.J., 2019. Modeling corticosteroid pharmacokinetics and pharmacodynamics, part II: sex differences in methylprednisolone pharmacokinetics and corticosterone suppression. Journal of Pharmacology and Experimental Therapeutics, 370(2), pp.327-336.
  12. Baek, I.H., 2019. Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. Xenobiotica, 49(6), pp.734-739.
  13. Baek, I.H., 2019. Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs. Xenobiotica, 49(8), pp.981-986.
  14. Barnes, W.G. and Hodges, G.R. eds., 2019. Aminoglycoside Antibiotics A Guide To Therapy. CRC Press.
  15. Blassmann, U., Hope, W., Roehr, A.C., Frey, O.R., Vetter-Kerkhoff, C., Thon, N., Briegel, J. and Huge, V., 2019. CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. Journal of Antimicrobial Chemotherapy, 74(4), pp.991-996.
  16. Borella, E., Oosterholt, S., Magni, P. and Della Pasqua, O., 2019. Use of prior knowledge and extrapolation in paediatric drug development: A case study with deferasirox. European Journal of Pharmaceutical Sciences, 136, p.104931.
  17. Bruno, A., Costantino, G., Sartori, L. and Radi, M., 2019. The in silico drug discovery toolbox: applications in lead discovery and optimization. Current Medicinal Chemistry, 26(21), pp.3838-3873.
  18. Bulitta, J.B., Jiao, Y., Landersdorfer, C.B., Sutaria, D.S., Tao, X., Shin, E., Höhl, R., Holzgrabe, U., Stephan, U. and Sörgel, F., 2019. Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. Pharmaceutics, 11(7), p.323.
  19. Bustamante, C., Ochoa, R., Asela, C. and Muskus, C., 2019. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations. Journal of computer-aided molecular design, 33(9), pp.845-854.
  20. Campagne, O., Davis, A., Zhong, B., Nair, S., Haberman, V., Patel, Y.T., Janke, L., Roussel, M.F. and Stewart, C.F., 2019. CNS penetration of cyclophosphamide and metabolites in mice bearing Group 3 medulloblastoma and non-tumor bearing mice. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 22(1), p.612.
  21. Chang, H.Y., Wu, S., Meno-Tetang, G. and Shah, D.K., 2019. A translational platform PBPK model for antibody disposition in the brain. Journal of Pharmacokinetics and Pharmacodynamics, 46(4), pp.319-338.
  22. Chauhan, M.K. and Bhatt, N., 2019. Bioavailability enhancement of polymyxin B with novel drug delivery: development and optimization using quality-by-design approach. Journal of pharmaceutical sciences, 108(4), pp.1521-1528.
  23. Cheng, D., Li, W., Wang, L., Lin, T., Poiani, G., Wassef, A., Hudlikar, R., Ondar, P., Brunetti, L. and Kong, A.N., 2019. Pharmacokinetics, pharmacodynamics, and PKPD modeling of curcumin in regulating antioxidant and epigenetic gene expression in healthy human volunteers. Molecular pharmaceutics, 16(5), pp.1881-1889.
  24. Crcek, M., Zdovc, J. and Kerec Kos, M., 2019. A review of population pharmacokinetic models of gentamicin in paediatric patients. Journal of clinical pharmacy and therapeutics, 44(5), pp.659-674.
  25. de Miranda Silva, C., Hajihosseini, A., Myrick, J., Nole, J., Louie, A., Schmidt, S. and Drusano, G.L., 2019. Effect of moxifloxacin plus pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay. Antimicrobial agents and chemotherapy, 63(1).
  26. Della Torre, M., Enakpene, C., Ravangard, S., DiGiovanni, L., Deyo, K., Whelan, A., Sutherland, M. and Fischer, J., 2019. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures. American Journal of Obstetrics & Gynecology MFM, 1(4), p.100051.
  27. Deyme, L., Barbolosi, D. and Gattacceca, F., 2019. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer chemotherapy and pharmacology, 83(1), pp.27-42.
  28. Drusano, G.L. and Louie, A., 2019. Breakpoint determination when multiple organisms are tested for effect targets. European Journal of Pharmaceutical Sciences, 130, pp.196-199.
  29. Drusano, G.L., Shields, R.K., Mtchedlidze, N., Nguyen, M.H., Clancy, C.J., Vicciarelli, M. and Louie, A., 2019. Pharmacodynamics of ceftazidime plus avibactam against KPC-2-bearing isolates of Klebsiella pneumoniae in a hollow fiber infection model. Antimicrobial agents and chemotherapy, 63(8), pp.e00462-19.
  30. Dunn, R.D., Crass, R.L., Hong, J., Pai, M.P. and Krop, L.C., 2019. Vancomycin volume of distribution estimation in adults with class III obesity. American Journal of Health-System Pharmacy, 76(24), pp.2013-2018.
  31. Finazzi, S., 2019. Mathematical Models for Optimisation of Drug Administration in Intensive Care Units(Doctoral dissertation, The Open University).
  32. Ghate, V.M., Chaudhari, P. and Lewis, S.A., 2019. Physiologically based pharmacokinetic (pbpk) modelling for in vitro-in vivo extrapolation: emphasis on the use of dissolution data. Dissolution Technologies, 26(03), pp.18-27.
  33. Greco, P., Regolisti, G., Maggiore, U., Ferioli, E., Fani, F., Locatelli, C., Parenti, E., Maccari, C., Gandolfini, I. and Fiaccadori, E., 2019. Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury. Journal of nephrology, 32(2), pp.297-306.
  34. Guan, X., Bryniarski, M.A. and Morris, M.E., 2019. In vitro and in vivo efficacy of the monocarboxylate transporter 1 inhibitor AR-C155858 in the Murine 4T1 breast cancer tumor model. The AAPS journal, 21(1), p.3.
  35. Hill, A.C., Rower, J.E. and White, H.S., 2019. The pharmacokinetics of oral carbamazepine in rats dosed using an automated drug delivery system. Epilepsia, 60(9), pp.1829-1837.
  36. Kim, T.H., Bulitta, J.B., Kim, D.H., Shin, S. and Shin, B.S., 2019. Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. International journal of pharmaceutics, 556, pp.276-286.
  37. Hughes, J.H., Upton, R.N., Reuter, S.E., Phelps, M.A. and Foster, D.J., 2019. Optimising time samples for determining area under the curve of pharmacokinetic data using non‐compartmental analysis. Journal of Pharmacy and Pharmacology, 71(11), pp.1635-1644.
  38. Kim, M., Son, H., Noh, K., Kim, E., Shin, B.S. and Kang, W., 2019. Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics, 11(3), p.133.
  39. Lee, K.W., Kim, T.H., Lee, J.B., Kim, K.S., Park, J.B., Gershkovich, P., Yoo, S.D., Shin, S., Shin, B.S. and Kim, S.J., 2019. Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. Journal of Pharmacological Sciences, 139(2), pp.65-71.
  40. Li, M., Nguyen, L., Subramaniyan, B., Bio, M., Peer, C.J., Kindrick, J., Figg, W.D., Woo, S. and You, Y., 2019. Pbpk modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release, 308, pp.86-97.
  41. Luo, D., Carter, K.A., Molins, E.A., Straubinger, N.L., Geng, J., Shao, S., Jusko, W.J., Straubinger, R.M. and Lovell, J.F., 2019. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. Journal of Controlled Release, 297, pp.39-47.
  42. Luo, W., Chen, D., Wu, M., Li, Z., Tao, Y., Liu, Q., Pan, Y., Qu, W., Yuan, Z. and Xie, S., 2019. Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents. Journal of Veterinary Science, 20(5).
  43. Mavroudis, P.D., Ayyar, V.S. and Jusko, W.J., 2019. ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models. CPT: pharmacometrics & systems pharmacology, 8(8), pp.557-566.
  44. Mitchell, A.B., Vasilyeva, A., Gajjar, A., Santana, V.M. and Stewart, C.F., 2019. Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. Pediatric blood & cancer, 66(4), p.e27578.
  45. Moore, H., 2019. The mathematical and computational sciences special interest group of the International Society of Pharmacometrics. CPT: pharmacometrics & systems pharmacology, 8(7), p.433.
  46. Muñoz, M., Olsen, P.S., Petersen, T.S., Manhart, S. and Waldorff, S., 2019. Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency. Basic & clinical pharmacology & toxicology, 125(2), pp.133-141.
  47. Nithya, S., Lalasa, M., Nagalakshmamma, K. and Archana, S., 2019, December. Computational Approaches in Toxicity Testing: An Overview. In International Conference On Computational And Bio Engineering(pp. 255-261). Springer, Cham.
  48. Niazi, S.K., 2019. Handbook of Pharmaceutical Manufacturing Formulations: Volume Two, Uncompressed Solid Products. CRC press.
  49. Oyaga-Iriarte, E., Insausti, A., Bueno, L., Sayar, O. and Aldaz, A., 2019. Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. Journal of Pharmacy & Pharmaceutical Sciences, 22, pp.112-121.
  50. Ooi, M.H., Ngu, S.J., Chor, Y.K., Li, J., Landersdorfer, C.B. and Nation, R.L., 2019. Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens. Clinical Infectious Diseases, 69(11), pp.1962-1968.
  51. Pan, S. and Duffull, S.B., 2019. Automated proper lumping for simplification of linear physiologically based pharmacokinetic systems. Journal of pharmacokinetics and pharmacodynamics, 46(4), pp.361-370.
  52. Patel, Y.T., Davis, A., Baker, S.J., Campagne, O. and Stewart, C.F., 2019. CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer chemotherapy and pharmacology, 84(2), pp.447-452.
  53. Polli, J.R., Engler, F.A. and Balthasar, J.P., 2019. Physiologically Based Modeling of the Pharmacokinetics of “Catch-and-Release” Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. Journal of pharmaceutical sciences, 108(1), pp.674-691.
  54. Ramakrishnan, V. and Mager, D.E., 2019. Pharmacodynamic models of differential bortezomib signaling across several cell lines of multiple myeloma. CPT: pharmacometrics & systems pharmacology, 8(3), pp.146-157.
  55. Rubino, C.M., Onufrak, N., Griffith, D.E., Bhavnani, S.M., Eagle, G. and Winthrop, K.L., 2019. Pharmacokinetic (PK) Evaluation of Amikacin Liposome Inhalation Suspension (ALIS) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease. In  ADVANCES IN THE TREATMENT OF NTM(pp. A2654-A2654). American Thoracic Society.
  56. Ruth, M.M., Magombedze, G., Gumbo, T., Bendet, P., Sangen, J.J., Zweijpfenning, S., Hoefsloot, W., Pennings, L., Koeken, V.A., Wertheim, H.F. and Lee, P.S., 2019. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. Journal of Antimicrobial Chemotherapy, 74(7), pp.1952-1961.
  57. Seng Yue, C., Ozdin, D., Selber‐Hnatiw, S. and Ducharme, M.P., 2019. Opportunities and Challenges Related to the Implementation of Model‐Based Bioequivalence Criteria. Clinical Pharmacology & Therapeutics, 105(2), pp.350-362.
  58. Serrano-Rodríguez, J.M., Mengual, C., Quirós-Carmona, S., Fernández, J., Domínguez, J.M., Serrano-Caballero, J.M., Morgaz, J., Navarrete-Calvo, R., Gómez-Villamandos, R.J. and del Mar Granados, M., 2019. Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. Veterinary anaesthesia and analgesia, 46(2), pp.226-235.
  59. Shah, N.R., Bulitta, J.B., Kinzig, M., Landersdorfer, C.B., Jiao, Y., Sutaria, D.S., Tao, X., Höhl, R., Holzgrabe, U., Kees, F. and Stephan, U., 2019. Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics, 11(6), p.286.
  60. Shenje, J., Gumbo, T., Wiesner, L., Ntsekhe, M., Mayosi, B. and Ross, I., 2019. Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. IJC Heart & Vasculature, 22, pp.105-110.
  61. Shetake, N.G., Kumar, A. and Pandey, B.N., 2019. Iron-oxide nanoparticles target intracellular HSP90 to induce tumor radio-sensitization. Biochimica et Biophysica Acta (BBA)-General Subjects, 1863(5), pp.857-869.
  62. Shin, S., Kim, T.H., Jeong, S.W., Chung, S.E., Lee, D.Y., Kim, D.H. and Shin, B.S., 2019. Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs. Plos one, 14(5), p.e0216875.
  63. Singh, A.P. and Shah, D.K., 2019. A “dual” cell-level systems PK-PD model to characterize the bystander effect of ADC. Journal of pharmaceutical sciences, 108(7), pp.2465-2475.
  64. Singh, A.P., Guo, L., Verma, A., Wong, G.G.L. and Shah, D.K., 2019. A cell-level systems PK-PD model to characterize in vivo efficacy of ADCs. Pharmaceutics, 11(2), p.98.
  65. Srinivas, N., Joseph, S.B., Robertson, K., Kincer, L.P., Menezes, P., Adamson, L., Schauer, A.P., Blake, K.H., White, N., Sykes, C. and Luciw, P., 2019. Predicting efavirenz concentrations in the brain tissue of HIV‐infected individuals and exploring their relationship to neurocognitive impairment. Clinical and translational science, 12(3), pp.302-311.
  66. Stewart, C., Campagne, O., Davis, A., Zhong, B., Nair, S., Haberman, V., Patel, Y.T., Janke, L. and Roussel, M.F., 2019. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice. Journal of Pharmacy & Pharmaceutical Sciences, 22, pp.612-629.
  67. Šturm, S., Škibin, A., Grabnar, I., Pogačnik, M. and Flajs, V.C., 2019. Industrial chemical bisphenol A and raw milk: a toxicokinetic study in lactating dairy sheep after repeated dietary and subcutaneous administration.
  68. Tebbens, J.D., Matonoha, C., Matthios, A. and Papáček, Š., 2019. On parameter estimation in an in vitro compartmental model for drug-induced enzyme production in pharmacotherapy. Applications of Mathematics, 64(2), pp.253-277.
  69. Yu, R., Song, D., DuBois, D.C., Almon, R.R. and Jusko, W.J., 2019. Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats. The AAPS journal, 21(5), p.93.
  70. Yuan, D., Rode, F. and Cao, Y., 2019. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. European Journal of Pharmaceutical Sciences, 138, p.105032.
  71. Seng Yue, C., Ozdin, D., Selber‐Hnatiw, S. and Ducharme, M.P., 2019. Opportunities and Challenges Related to the Implementation of Model‐Based Bioequivalence Criteria. Clinical Pharmacology & Therapeutics, 105(2), pp.350-362.
  72. Zhang, L. and Mager, D.E., 2019. Systems modeling of bortezomib and dexamethasone combinatorial effects on bone homeostasis in multiple myeloma patients. Journal of pharmaceutical sciences, 108(1), pp.732-740.